Cutaneous mastocytosis: A review focusing on the pediatric population

Clinical Pediatrics

Volumn 47, Issue 8, 2008, Pages 757-761

  Briley, Laura D ^a   Phillips, Charles M ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Mast cell disease; Mastocytoma; Mastocytosis; Urticaria pigmentosa

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMPHOTERICIN B; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CROMOGLYCATE DISODIUM; DEXCHLORPHENIRAMINE; DOXEPIN; HYDROXYZINE; IODINE; KETOTIFEN; LORATADINE; MEQUITAZINE; MIZOLASTINE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POLYMYXIN B; PREDNISONE; RANITIDINE; SCOPOLAMINE; THIAMINE; TRIAMCINOLONE ACETONIDE;

CLINICAL FEATURE; DIARRHEA; DIFFUSE CUTANEOUS MASTOCYTOSIS; DRUG ACTIVITY; HUMAN; MASTOCYTOMA; MASTOCYTOSIS; PEPTIC ULCER; REVIEW; SEDATION; SIDE EFFECT; SKIN ATROPHY; SURGICAL TECHNIQUE; TELANGIECTASIA; TREATMENT RESPONSE; URTICARIA PIGMENTOSA;

CHILD; DIAGNOSIS, DIFFERENTIAL; HUMANS; MASTOCYTOSIS, CUTANEOUS; PROGNOSIS;

EID: 50949086145     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922808318344     Document Type: Review

References (14)

1. Bolognia JL, Jorizzo JL, Rapini RP Dermatology. New York, NY: Mosby, 2003.
2. Longley BJ, Duffy TP, Kohn S. The mast cell and mast cell disease. J Am Acad Dermatol. 1995 ; 32: 545-561.
3. Katsamba AD, Karpouzis AJ, Koumantaki-Mathioudaki E., Jorizzo JL Mastocytosis with skin manifestations: current status. J Eur Acad Dermatol Venereol. 1999 ; 13: 155-165.
4. Hannaford RM, Rogers M. Presentation of cutaneous mastocytosis in 173 children. Aust J Dermatol. 2001 ; 42: 15-21.
5. Kettelhut BD, Metcalfe D. Pediatric Mastocytosis. J Invest Dermatol. 1991 ; 96: 15S - 18S.
6. Heide R., Tank B., Oranje AP Mastocytosis in childhood. Pediatr Dermatol. 2002 ; 19: 375-381.
7. Buttner C., Henz BM, Welker P., Sepp NT, Grabbe J. Identification of activating c-kit mutations in adult, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior. J Invest Dermatol. 1998 ; 111: 1227-1231.
8. Valent P., Akin C., Sperr WR, et al. Mastocytosis: pathology, genetics and current options for therapy. Leuk Lymphoma. 2005 ; 46: 35-48.
9. Brockow K., Akin KC, Huber M., Metcalfe DD Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003 ; 48: 508-516.
10. Akoglu G., Erkin G., Cakir B., et al. Cutaneous mastocytosis: demographic aspects and clinical features of 55 patients. J Eur Acad Dermatol Venereol. 2006 ; 20: 969-973.
11. Wolff K. Komar M. Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001 ; 25: 519-528.
12. Bachmeyer C., Guillemette J., Blum L., et al. Telangiectasia macularis eruptive perstans and multiple myeloma. J Am Acad Dermatol. 2000 ; 43: 972-974.
13. Czarnetzki M., Behrendt H. Urticaria pigmentosa: clinical picture and response to oral disodium cromoglycate. Br J Dermatol. 1981 ; 105: 536-567.
14. Okayama Y., Benyon RC, Rees PH, Lowman MA, Hillier K., Church MK Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy. 1992 ; 22: 401-409.